Loading...
ABP 215 and bevacizumab in NSCLC patients: time course and magnitude of response in the phase 3 comparative trial (MAPLE)
Thatcher, Nick Goldschmidt, J Thomas, M Schenker, M Pan, Z Hanes, V
Thatcher, Nick
Goldschmidt, J
Thomas, M
Schenker, M
Pan, Z
Hanes, V
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Thatcher N, Goldschmidt J, Thomas M, Schenker M, Pan Z, Hanes V. P2.13-40ABP 215 and bevacizumab in NSCLC patients: time course and magnitude of response in the phase 3 comparative trial (MAPLE). J Thorac Oncol. 2018 Oct;13(10):S814.